Lung Surfactants Market Size & Industry Share - Growth Trends & Forecasts (2026 - 2033)

Based on the Drug Type :

The drug type segment is categorized into lucinactant, colfosceril palmitate, beractant, calefacient, protectant alfa. In 2025, the lucinactant segment accounted for the highest market share in the overall lung surfactants market. Lucinactant is a synthetic lung surfactant that is designed to mimic the properties and functions of natural lung surfactants. It is composed of a mixture of lipids and proteins. Lucinactant is primarily used for the prevention and treatment of respiratory distress syndrome (RDS) in premature infants. For instance, according to the data published by the World Health Organization (WHO), it is estimated that about 13.4 million babies were born preterm in 2020 (before 37 completed weeks of gestation).

However, the Beractant segment is expected to be the fastest-growing segment during the forecast period. Due to its established efficacy and long-standing use in neonatal care. It is a natural lung surfactant derived from minced bovine lings. Furthermore, the increasing preterm birth rate and other factors led to the demand for lucinactant for the treatment of respiratory distress syndrome (RDS) in babies. Which in turn, accelerates the growth of the market.

Based on the Indication :

The indication segment is categorized into respiratory distress syndrome (RDS), respiratory infections, and others. In 2025, the respiratory distress syndrome (RDS) segment accounted for the highest market share in the Lung Surfactants market. RDS occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. For instance, as per the article published by the National Institute of Health (NIH) in 2019, In the United States, respiratory distress syndrome (RDS) is seen in about 1.00% of pregnancies and affects 20,000 to 30,000 infants each year. The increased rate of respiratory distress syndrome in premature babies is driving the growth of the segment.

However, the respiratory infection segment is expected to be the fastest-growing segment during the forecast period. The use of lung surfactants is used in respiratory infection to improve lung function and facilitate oxygenation in adults and children. which, in turn, is driving the segment growth. Furthermore, above mentioned factors are increasing the growth of the respiratory distress syndrome segment.

Based on the Distribution Channel :

The distribution channel segment is categorized into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2025, the hospital pharmacy segment accounted for the highest market share in the lung surfactants market. Hospital pharmacies serve as a primary distribution channel for lung surfactants. They are responsible for procuring and stocking lung surfactant products, ensuring their availability for healthcare professionals and patients within the hospital setting. hospital pharmacy plays a crucial role in the distribution of lung surfactant market. As they directly supply the product to the Neonatal Care Units ( NCUs) in the hospital ensuring to timely availability of the drugs.

However, the retail pharmacy segment is expected to be the fastest-growing segment during the forecast period. The retail pharmacy is more common in regions where lung surfactants are available for home use or administration by healthcare professionals outside of hospital settings. Hence, above mentioned factors are driving the growth of the market.

Based on the End-User :

The end user segment is categorized into hospitals, specialty clinics, and others. In 2022, the hospital segment accounted for the highest market share of 45.50% in the lung surfactants market. Hospitals, including neonatal intensive care units (NICUs), are the primary end user of lung surfactant products. These facilities have the infrastructure, equipment, and specialized healthcare professionals to administer lung surfactant therapy to premature infants with respiratory distress syndrome (RDS). Hospitals typically procure the drugs from manufacturers or through authorized distributors. For instance, according to the report of the National Organization Of Rare Disorders, hospital mortality for Acute respiratory distress syndrome (ARDS) is about 40-50.00%. Thus the increasing mortality rate for respiratory distress syndrome (RDS) is driving the growth of the segment.

However, the specialty clinics segment is expected to be the fastest-growing segment during the forecast period. This is because of well-established specialty clinics in countries such as the U.S. and China. Furthermore, the above mentioned factors will drive the growth of the lung surfactant in the market.

Based on the Region :

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 36.85% and was valued at USD 66.49 million, and is expected to reach USD 102.16 million in 2033. In North America, the U.S. accounted for the highest market share of 68.20% during the base year of 2025. This is due to the advanced healthcare infrastructure, high prevalence of premature births, and well-established neonatal care units in the regions. For instance, in 2021, as per the data published by Yale Medicine Organization, about 190,000 Americans were diagnosed with Acute Respiratory Distress Syndrome (ARDS) each year in the U.S.

Furthermore, Asia Pacific is expected to witness significant growth over the forecast period, growing at a CAGR of 4.80% during 2026-20230. This is attributed to the increasing awareness of lung surfactant therapy and rising healthcare expenditure in the Asia Pacific. Hence, above mentioned factors are driving the market growth in the region.